66 related articles for article (PubMed ID: 21275968)
1. CD200 expression in plasma cell myeloma.
Olteanu H; Harrington AM; Hari P; Kroft SH
Br J Haematol; 2011 May; 153(3):408-11. PubMed ID: 21275968
[No Abstract] [Full Text] [Related]
2. CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials?
Lee C; Guinn BA; Brooks SE; Richardson D; Orchard K
Br J Haematol; 2010 Jun; 149(5):795-6. PubMed ID: 20230402
[No Abstract] [Full Text] [Related]
3. CD200: a putative therapeutic target in cancer.
Moreaux J; Veyrune JL; Reme T; De Vos J; Klein B
Biochem Biophys Res Commun; 2008 Feb; 366(1):117-22. PubMed ID: 18060862
[TBL] [Abstract][Full Text] [Related]
4. CD20-positive multiple myeloma - differential expression of cyclins D1 and D2 suggests a heterogeneous disease.
Quinn J; Percy L; Glassford J; Somana K; Rodriguez-Justo M; Yong K
Br J Haematol; 2010 Apr; 149(1):156-9. PubMed ID: 19995388
[No Abstract] [Full Text] [Related]
5. CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.
Conticello C; Giuffrida R; Parrinello N; Buccheri S; Adamo L; Sciuto MR; Colarossi C; Aiello E; Chiarenza A; Romano A; Salomone E; Gulisano M; Giustolisi R; Di Raimondo F
Leuk Res; 2013 Dec; 37(12):1616-21. PubMed ID: 24183830
[TBL] [Abstract][Full Text] [Related]
6. CD138 shedding in plasma cell myeloma.
Grigoriadis G; Whitehead S
Br J Haematol; 2010 Aug; 150(3):249. PubMed ID: 20433680
[No Abstract] [Full Text] [Related]
7. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
8. Instability of immunophenotype in plasma cell myeloma.
Cao W; Goolsby CL; Nelson BP; Singhal S; Mehta J; Peterson LC
Am J Clin Pathol; 2008 Jun; 129(6):926-33. PubMed ID: 18480010
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma.
Aref S; Azmy E; El-Gilany AH
Hematol Oncol; 2017 Mar; 35(1):51-57. PubMed ID: 26033514
[TBL] [Abstract][Full Text] [Related]
11. [CD200 protein, bad prognostic in patients with multiple myeloma].
Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Pérez-Retiguin F; Reyes-Maldonado E; Maillet D; Montiel-Cervantes LA
Rev Med Inst Mex Seguro Soc; 2015; 53(4):438-43. PubMed ID: 26177431
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD56/NCAM on hematopoietic malignant cells. A useful marker for acute monocytic and megakaryocytic leukemias.
Ikushima S; Yoshihara T; Matsumura T; Misawa S; Morioka Y; Hibi S; Imashuku S
Int J Hematol; 1991 Oct; 54(5):395-403. PubMed ID: 1721853
[TBL] [Abstract][Full Text] [Related]
14. Lack of CD27 in myeloma delineates different presentation and outcome.
Moreau P; Robillard N; Jégo G; Pellat C; Le Gouill S; Thoumi S; Avet-Loiseau H; Harousseau JL; Bataille R
Br J Haematol; 2006 Jan; 132(2):168-70. PubMed ID: 16398651
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
[TBL] [Abstract][Full Text] [Related]
16. Markers of multiple hematopoietic-cell lineages in multiple myeloma.
Epstein J; Xiao HQ; He XY
N Engl J Med; 1990 Mar; 322(10):664-8. PubMed ID: 2137556
[TBL] [Abstract][Full Text] [Related]
17. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C; Zustin J; Jacobsen F; Luetkens T; Kröger N; Schilling G; Bokemeyer C; Sauter G; Atanackovic D; Marx A
Exp Mol Pathol; 2010 Oct; 89(2):175-81. PubMed ID: 20621094
[TBL] [Abstract][Full Text] [Related]
19. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.
Armellini A; Sarasquete ME; García-Sanz R; Chillón MC; Balanzategui A; Alcoceba M; Fuertes M; López R; Hernández JM; Fernández-Calvo J; Sierra M; Megido M; Orfão A; Gutiérrez NC; González M; San Miguel JF
Br J Haematol; 2008 Apr; 141(2):212-5. PubMed ID: 18353163
[TBL] [Abstract][Full Text] [Related]
20. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions.
Koning N; Swaab DF; Hoek RM; Huitinga I
J Neuropathol Exp Neurol; 2009 Feb; 68(2):159-67. PubMed ID: 19151626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
